| Prev Close | 105.26 |
| Open | 105.06 |
| Day Low/High | 103.10 / 106.08 |
| 52 Wk Low/High | 70.76 / 153.99 |
| Volume | 137.94K |
| Avg Volume | 997.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 100.52M |
| Market Cap | 10.52B |
| EPS | -5.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR)...
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide "Helping Hands" Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylam's Board of Directors, effective June 1, 2018.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA (siRNA) conjugates to the central nervous system (CNS) and is planning to advance a...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2018 and highlighted recent progress in advancing its pipeline.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has reached alignment with the U.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Deutsche Bank 43 rd Annual Healthcare Conference on Tuesday, May 8, 2018...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2018 on Thursday, May 3, 2018, after the U.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis,...
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has entered into a settlement agreement with Dicerna Pharmaceuticals resolving trade secret misappropriation claims against Dicerna, and...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present new results from the Phase 1 and Phase 1/2 open-label extension...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented new results from the APOLLO Phase 3 study of patisiran, an investigational, RNAi...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for lumasiran...
Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17 th Annual Needham Healthcare Conference on Wednesday,...
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational therapeutic for the treatment...
For many people living with a rare disease, such as hereditary ATTR (hATTR) amyloidosis, it can take years to be accurately diagnosed.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Sanofi Genzyme has declined its opt-in for the development and commercialization of lumasiran (ALN-GO1), an...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen and Company...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2017 and highlighted recent progress in...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 20 th Annual BIO CEO...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated its...
